Dalfampridine
Other Nervous System Drugs
- Drug class
- Other Nervous System Drugs
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 750
Overview
Plain-language summary, compiled from the cited regulatory records
Dalfampridine is a medication classified as an "Other Nervous System Drug" [1]. It functions as a potassium channel blocker [1].
Dalfampridine is approved for use in adult patients diagnosed with multiple sclerosis (MS) [1]. Its indication is to improve walking ability in these patients, which has been demonstrated by an observed increase in walking speed [1].
In the past 12 months, there have been 750 adverse event reports associated with dalfampridine [2]. Some of the most frequently reported adverse events include multiple sclerosis relapse, multiple sclerosis itself, the perception of the drug being ineffective, falls, and fatigue [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | February 12, 2024 |
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ].
Dalfampridine is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed ( 1 , 14 ).
How to take
Drug interactions
Known interactions involving Dalfampridine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 1134ac0f-59c1-a2… · revised February 12, 2024 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.